REGN — Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenues: Increased by 19% year-over-year to $3.6 billion.
• Non-GAAP Earnings Per Share: Rose 15% to $9.47, with net income of $1 billion.
• DUPIXENT Sales: Global net sales reached $4.9 billion, up 31% on a constant currency basis.
• EYLEA HD Sales: U.S. net product sales grew 52% year-over-year to $468 million.
• Libtayo Sales: Global product sales increased by 54% to $438 million.
• Sanofi Collaboration Revenue: Totaled $1.6 billion, with Regeneron's share of profits growing 42% year-over-year.

2. Strategic Updates and Business Highlights

• DUPIXENT: Continues to expand its market presence with new approvals for allergic fungal rhinosinusitis and chronic spontaneous urticaria, targeting a broader patient demographic.
• EYLEA HD: Resubmitted application for FDA approval of a prefilled syringe; pending regulatory decisions expected this quarter.
• Pipeline Progress: FDA approval of Otarmeni for genetic hearing loss; positive Phase III data for cemdisiran in generalized myasthenia gravis; and advancements in obesity treatments with olatorepatide.
• Capital Allocation: Announced a new $3 billion share repurchase program, reflecting confidence in the business.
• Government Agreement: Entered into a Most Favored Nation pricing agreement with the U.S. government to lower drug prices while maintaining innovation.

3. Forward Guidance and Outlook

• Sanofi Collaboration: Expected to fully repay the development balance by the end of Q2 2026, which will enhance collaboration revenue.
• Earnings Guidance: Adjusted GAAP gross margin guidance to 77%-78% due to temporary manufacturing interruptions.
• Pipeline Expectations: Anticipating regulatory decisions on cemdisiran and garetosmab in the upcoming quarters, with continued investment in R&D.

4. Bad News, Challenges, or Points of Concern

• EYLEA Sales Decline: Traditional EYLEA sales fell 36% year-over-year to $473 million, attributed to competitive pressures and patient affordability issues.
• Manufacturing Issues: Temporary interruptions at the Limerick, Ireland facility impacted GAAP gross margins and production timelines.
• Regulatory Delays: The FDA did not act by the April 2026 PDUFA date for the EYLEA HD prefilled syringe application, raising concerns about potential backlog issues.

5. Notable Q&A Insights

• DUPIXENT Collaboration: Management expressed openness to collaboration with Sanofi on life cycle expansions, highlighting the product's strong performance.
• Fianlimab in Lung Cancer: No plans to move to Phase III due to lack of compelling data; focus remains on melanoma.
• EYLEA Prefilled Syringe: Management indicated optimism regarding FDA approval, pending positive inspection outcomes.
• Lynozyfic and Infection Risks: Discussed the competitive landscape in multiple myeloma, emphasizing the need to mitigate infection risks associated with bispecific therapies.
• Next-Gen DUPIXENT: Ongoing discussions about the importance of advancing late-stage programs before existing patents expire, with a focus on leveraging immunology expertise.

Overall, Regeneron reported a robust start to 2026, driven by strong sales in key products and strategic advancements in its pipeline, while also facing challenges in certain areas that could impact future performance.